A Non-Interventional, Multicenter, Multicohort Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Subcutaneous Atezolizumab in Participants Treated in Routine Clinical Practice
A Non-Interventional, Multicenter, Multicohort Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Subcutaneous Atezolizumab in Participants Treated in Routine Clinical Practice
This is a non-interventional, multi-country, multi-centre, multicohort, primary data collection study, designed to assess patients' reported satisfaction with Atezolizumab Subcutenous (SC) treatment and Health-related Quality of Life (HRQoL), as well as the effectiveness and safety of Atezolizumab SC in participants treated for selected approved indications in routine clinical practice.
Inclusion Criteria:
Participants must have one of the following confirmed diagnoses for which atezolizumab is approved in the local SmPC:
Should not have received > 4 prior cycles of IV Atezolizumab
Exclusion Criteria:
global-roche-genentech-trials@gene.com888-662-6728 (U.S. and Canada)
Mont-godinne, 5530, Belgium
Acquaviva Delle Fonti, Piedmont 70021, Italy
Fano (PU), The Marches 61032, Italy
Krakow, 31-115, Poland
Cluj-Napoca, 400162, Romania
Galati, 800578, Romania
Alcázar de San Juan, Ciudad REAL 13600, Spain
Alcázar de San Juan, Ciudad REAL 13600, Spain
Santiago de Compostela, LA Coruna 15706, Spain
Santa Cruz de Tenerife, Tenerife 38010, Spain
Norfolk, NR31 6LA, United Kingdom